Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?
Jiali Wang,1,2 Yixuan Zhang,1,2 Xiaoquan Liu,1,2 Haochen Liu1,2 1School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 2Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, People’s Republic of ChinaCorresponden...
Enregistré dans:
Auteurs principaux: | Wang J, Zhang Y, Liu X, Liu H |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8d0e87111a09445f9834725a0e68eb9c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation
par: Jiali Wang, et autres
Publié: (2021) -
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
par: Yu D, et autres
Publié: (2021) -
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
par: Klempner SJ, et autres
Publié: (2017) -
Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
par: Sergey V. Goryaynov
Publié: (2021) -
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
par: Zhu VW, et autres
Publié: (2019)